<DOC>
	<DOCNO>NCT02177838</DOCNO>
	<brief_summary>This pilot clinical trial study cetuximab radiation therapy treat patient stage III-IV head neck cancer . Monoclonal antibody , cetuximab , may block tumor growth different way target certain cell . Radiation therapy use high energy x ray kill tumor cell . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving cetuximab cisplatin together radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Cetuximab Radiation Therapy Treating Patients With Stage III-IV Head Neck Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . 2 year ( yr ) locoregional control cetuximab responder . SECONDARY OBJECTIVES : I. Assess secondary clinical endpoint percent patient receive neoadjuvant cetuximab progress compute tomography ( CT ) Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion neoadjuvant cetuximab , 2 yr locoregional control non-responders neoadjuvant cetuximab , complete response rate positron emission tomography ( PET ) /computed tomography ( CT ) scan 3 month completion radiation therapy responder non-responders neoadjuvant cetuximab . II . Analyze relationship know deoxyribonucleic acid ( DNA ) mutation tumor per FoundationOne genomic profile , correlate clinical endpoint locoregional control . II . Analyze change protein production tumor response 3 week cetuximab . III . Analyze change protein production skin response 3 week cetuximab . IV . To investigate whether tumor image characteristic include anatomical molecular parameter evaluate PET/CT , either alone combined biomarkers attribute good prediction clinical outcome , response neoadjuvant cetuximab ; final clinical endpoint , 2-year local regional control . OUTLINE : Patients receive cetuximab intravenously ( IV ) 60-120 minute 3 week . Patients undergo external beam radiation therapy ( EBRT ) 6-7 week . Patients achieve response continue weekly dos cetuximab radiation therapy complete . Patients unable achieve response progression receive cisplatin IV 1-2 hour day 1 , 22 , 43 radiation therapy . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Verrucous</mesh_term>
	<mesh_term>Tongue Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven squamous cell carcinoma oropharynx , hypopharynx larynx Stage III/IVa/b squamous cell carcinoma ( SCC ) American Joint Committee Cancer ( AJCC ) 7 criterion ( advanced , metastatic ) Patients must give informed consent Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Platelets &gt; = 100,000/uL Absolute neutrophil count ( ANC ) &gt; = 1,500/uL Hemoglobin &gt; 8 g/dl ( use transfusion achieve acceptable ) Total bilirubin &lt; 2 X institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3 X institutional ULN Serum creatinine &lt; 2 x institutional ULN creatinine clearance &gt; 50 ml/min determine 24 hour collection estimate CockcroftGault formula Estimated life expectancy least 12 week Negative pregnancy test Patients may receive previous therapy head neck SCC , include chemotherapy , radiation therapy , surgery beyond biopsy Second primary malignancy ; exception 1 ) patient second primary malignancy treat disease free least 3 year , 2 ) situ carcinoma ( e.g . situ carcinoma cervix ) , 3 ) nonmelanomatous carcinoma skin Patients metastatic disease beyond neck supraclavicular region exclude Serious concomitant systemic disorder ( include active infection ) would compromise safety patient compromise patient 's ability complete study , discretion investigator ; include scleroderma History allergic reaction attribute compound similar chemical biologic composition cetuximab cisplatinum agent use study Women pregnant ; woman childbearing age must agree undergo pregnancy test prior therapy use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation 6 month ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Patients human immunodeficiency virus ( HIV ) infection automatically exclude , must meet following criterion : cluster differentiation ( CD ) 4 count &gt; 499/cu mm viral load &lt; 50 copies/ml ; use highly active antiretroviral therapy ( HAART ) allow Patients either myocardial infarction , coronary artery bypass graft , coronary artery stenting , hospital admission heart relate issue congestive heart failure arrhythmia within last 3 month , allow protocol Grade 34 electrolyte abnormality ( Common Terminology Criteria Adverse Events [ CTCAE ] , version [ v ] . 4 ) : Serum calcium ( ionize adjust albumin ) &lt; 7 mg/dl ( 1.75 mmol/L ) &gt; 12.5 mg/dl ( &gt; 3.1 mmol/L ) despite intervention normalize level Magnesium &lt; 0.9 mg/dl ( &lt; 0.4 mmol/L ) &gt; 3 mg/dl ( &gt; 1.23 mmol/L ) despite intervention normalize level Potassium &lt; 3.5 mmol/L &gt; 6 mmol/L despite intervention normalize level Sodium &lt; 130 mmol/L &gt; 155 mmol/L despite intervention normalize level</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>